Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor-Reference-Cited by-同舟云学术

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor

Published:2017-02-03 Issue:5 Volume:45 Page:2294-2306
ISSN:0305-1048
Container-title:Nucleic Acids Research
language:en
Short-container-title:

Author:

Schmidt Karsten,Prakash Thazha P.,Donner Aaron J.,Kinberger Garth A.,Gaus Hans J.,Low Audrey,Østergaard Michael E.,Bell Melanie,Swayze Eric E.,Seth Punit P.

Publisher

Oxford University Press (OUP)

Subject

Genetics

Link

http://academic.oup.com/nar/article-pdf/45/5/2294/10911887/gkx060.pdf

Reference40 articles.

1. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials;Lancet

2. Asialoglycoprotein receptor mediated hepatocyte targeting — strategies and applications;J. Control. Release,2015

3. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor;J. Mol. Biol.,2000

4. Dynamic interactions of the asialoglycoprotein receptor subunits with coated pits. Enhanced interactions of H2 following association with H1;J. Biol. Chem.,1994

5. Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit: its obligate requirement for the stable expression of oligomeric receptor;J. Biol. Chem.,2001

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antisense Oligonucleotide Embedded Context Responsive Nanoparticles Derived from Synthetic Ionizable Lipids for lncRNA Targeted Therapy of Breast Cancer;ACS Applied Materials & Interfaces;2024-08-20

2. Safety and Tolerability of GalNAc₃-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data;Nucleic Acid Therapeutics;2024-02-01

3. Evolving Therapeutic Targets;Clinical Lipidology;2024

4. Development of an Optimized Process for the Liver-Targeted Triantennary N-Acetylgalactosamine Ligand;Organic Process Research & Development;2023-12-14

5. Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-12